BibTex RIS Cite

Serum S-100B levels in children with Subacute Sclerosing Panencephalitis

Year 2012, , 331 - 334, 01.09.2012
https://doi.org/10.5799/ahinjs.01.2012.03.0173

Abstract

Objectives: S-100B a protein prevalent in the central nervous system is a peripheral biomarker for blood-brain barrier disruption and neuronal damage. The objective of the study was to investigate the S-100B levels in patients with subacute sclerosing panencephalitis. Materials and methods: A group of 40 patients with SSPE and 40 healthy controls were recruited. Serum S-100B protein concentrations were measured using a commercially available electrochemiluminescence immunoassay (ECLIA) kit, as supplied and according to the manufacturer's standards. Results: Median S-100B levels were 0.095 ± 0.017 μg/L in patients with SSPE and 0.097±0.019 μg/L in the control group. This difference was not statistically significant (p>0.05). The patient group was further subdivided into two subgroups according to the presence or absence of brain atrophy. The S-100B levels were 0.096 ± 0.018 μg/L in the subgroup with atrophy and 0.094±0.014 μg/L in the subgroup without atrophy. This difference was also not statistically significant (p>0.05). Conclusions: Our results suggest that serum S-100B is not a reliable marker for neuronal damage in SSPE.

References

  • Garg RK. Subacute sclerosing panencephalitis. J Neu- rol 2008;14(12):1439-52.
  • Geyer C, Ulrich A, Grafe G, stach B, Till H. Diagnostic value of S 100B and neuron- specific enolase in mild pediatric traumatic brain injury. J neurosurg Pediatr 2009;4(2):339-44.
  • Schulpis KH, Margeli A, Akalestos A, et al. Effects of mode of delivery on maternal-neonatal plasma anti- oxidant status and on protein S-100B serum concen- trations. Scand J Clin Lab Invest 2006;66(6):733-42.
  • Gazzolo D, Abella R, Marinoni E, et al. New markers of neonatal neurology. J Maternal-Fetal Neonat Med 2009;12(1): 1-5.
  • Rothermundt M, Peters M, Prehn JH, Arolt V. S100B in brain damage and neurodegenaration. Microsc Res Tech 2003;60(5):614-32.
  • Dyken PR. Subacute sclerosing panencephalitis. Neu- rol Clin 1985;3(2):179-95.
  • Jabbour JT, Garcia JH, Lemmi H, Ragland J, Duenas DA, Sever JL. Subacute sclerosing pan encephalitis. JAMA 1969;207(12):2248-54.
  • Oztürk A, Gürses C, Baykan B, Gökyigit A, Eraksoy M. Subacute sclerosing panencephalitis: Clinical and magnetic resonance imaging evaluation of 36 pa- tients. J Child Neurol 2002;17(1):25-9.
  • Aydin K, Okur O, Tatli B, Sarwar SG, Ozturk C, Dilber C. Reduced gray matter volume in the frontotemporal cortex of patients with early subacute sclerosing pan- encephalitis. AJNR Am J Neuroradiol 2009;30(2):271- 5.
  • Lins H, Wallesch CW, Wunderlich MT. Sequential analyses of neurobiochemical markers of cerebral damage in cerebrospinal fluid and serum in CNS in- fections. Acta Neurol Scand 2005;112(2):303-08.
  • Ahlemeyer B, Beier H, Semkova I, Schaper C, Kriegl- stein J. S-100beta protects cultured neurons against glutamate- and staurosporine-induced damage and is involved in the antiapoptotic action of the 5 HT(1A)- receptor agonist, Bay x 3702. Brain Res 2000;858(1): 121-8.
  • Van Eldik LJ, Wainwright MS. The Janus face of glial derived S100B: beneficial and detrimental functions in the brain. Restor Neurol Neurosci 2003;21(3-4):97- 108.
  • Giussani DA, Thakor AS, Frulio R, Gazzolo D. Acute hypoxia increases S100beta protein in association with blood flow redistribution away from peripheral cir- culations in fetal sheep. Pediatr Res 2005;58(2):179- 84.
  • Oses JP, Leke R, Portela LV, et al. Biochemical brain markers and purinergic parameters in rat CSF after seizure induced by pentylenetetrazol. Brain Res Bull 2004; 64(2): 237-42.
  • Simonian NA, Coyle JT. Oxidative Stres in Neuro- degenerative Diseases. Ann Rev Pharmacol Toxicol 1996;36(1):83-106.
  • Michael T, Lin, M. Mitochondrial dysfunction and oxi- dative stress in neurodegenerative diseases. Nature 2006;443(3):787-95.
  • Li SW, Barger L, Liu RE, Mrak MST. S100b induction of the proinflammatory cytokine interleukin-6 in neu- rons. J Neurochem 2000;74(1):143-50.
  • Yuksel D, Yilmaz D, Uyar NY, Senbil N, Gurer Y, Anlar B. Tau proteins in the cerebrospinal fluid of patients with subacute sclerosing panencephalitis. Brain Dev 2010;32(3): 467-71.
  • Wiesmann M, Wandinger KP, Missler U, Eckhoff D, Rothermundt M, Arolt V, et al. Elevated plasma levels of S-100b protein in schizophrenic patients. Biol Psy- chiatry 1999;45:1508-11.
  • Chaves ML, Camozzato AL, Ferreira ED, et al. Se- rum levels of S100B and NSE proteins in Alzheimer’s disease patients. J Neuroinflammation 2010; 7(1):1-6.
  • Gazzolo D, Grutzfeld Dariusz, et al. Increased S100B in cerebrospinal fluid of infants with bacterial menin- gitis: Relationship to brain damage and routine cere- brospinal fluid findings. Clin Chem 2004;50(8):941-4.

Subakut Sklerozan Panensefalit\'li çocuklarda serum S-100B düzeyleri

Year 2012, , 331 - 334, 01.09.2012
https://doi.org/10.5799/ahinjs.01.2012.03.0173

Abstract

Amaç: S-100B santral sinir sisteminde yaygın olarak bulunan, kan beyin bariyeri yıkımında ve nöronal hasarda periferik belirteç olarak kullanılan bir proteindir. Bu çalışmanın amacı, Subakut sklerozan panensefalitli hastalarda S-100B düzeylerini araştırmaktır. Gereç ve yöntem: Çalışmada, SSPE\' li 40 hasta ile 40 sağlıklı kontrol grubu alındı. Serum S-100B protein konsantrasyonları elektrokemiluminesan immunoassay (ECLIA) yöntemi ile üretici standartlarına göre ölçüldü. Bulgular: Ortalama S-100B seviyeleri SSPE\'li hasta grubunda 0.095 ± 0.017 μg/L, kontrol grubunda ise 0.097 ± 0.019 μg/L bulundu. Aralarında istatistiksel olarak anlamlı farklılık bulunmadı (p>0.05). Hasta grubu beyin atrofisinin varlığına göre iki altgruba ayrıldı. S-100B seviyeleri beyin atrofisi olan grupta 0.096±0.018 μg/L, atrofisi olmayan grupta ise 0.094±0.014 μg/L idi. Bu farklılık istatistiksel olarak anlamlı değildi (p>0.05). Sonuç: Bizim sonuçlarımız, S-100B\'nin SSPE\' de nöronal hasarda güvenilir bir belirteç olmadığını göstermektedir.

References

  • Garg RK. Subacute sclerosing panencephalitis. J Neu- rol 2008;14(12):1439-52.
  • Geyer C, Ulrich A, Grafe G, stach B, Till H. Diagnostic value of S 100B and neuron- specific enolase in mild pediatric traumatic brain injury. J neurosurg Pediatr 2009;4(2):339-44.
  • Schulpis KH, Margeli A, Akalestos A, et al. Effects of mode of delivery on maternal-neonatal plasma anti- oxidant status and on protein S-100B serum concen- trations. Scand J Clin Lab Invest 2006;66(6):733-42.
  • Gazzolo D, Abella R, Marinoni E, et al. New markers of neonatal neurology. J Maternal-Fetal Neonat Med 2009;12(1): 1-5.
  • Rothermundt M, Peters M, Prehn JH, Arolt V. S100B in brain damage and neurodegenaration. Microsc Res Tech 2003;60(5):614-32.
  • Dyken PR. Subacute sclerosing panencephalitis. Neu- rol Clin 1985;3(2):179-95.
  • Jabbour JT, Garcia JH, Lemmi H, Ragland J, Duenas DA, Sever JL. Subacute sclerosing pan encephalitis. JAMA 1969;207(12):2248-54.
  • Oztürk A, Gürses C, Baykan B, Gökyigit A, Eraksoy M. Subacute sclerosing panencephalitis: Clinical and magnetic resonance imaging evaluation of 36 pa- tients. J Child Neurol 2002;17(1):25-9.
  • Aydin K, Okur O, Tatli B, Sarwar SG, Ozturk C, Dilber C. Reduced gray matter volume in the frontotemporal cortex of patients with early subacute sclerosing pan- encephalitis. AJNR Am J Neuroradiol 2009;30(2):271- 5.
  • Lins H, Wallesch CW, Wunderlich MT. Sequential analyses of neurobiochemical markers of cerebral damage in cerebrospinal fluid and serum in CNS in- fections. Acta Neurol Scand 2005;112(2):303-08.
  • Ahlemeyer B, Beier H, Semkova I, Schaper C, Kriegl- stein J. S-100beta protects cultured neurons against glutamate- and staurosporine-induced damage and is involved in the antiapoptotic action of the 5 HT(1A)- receptor agonist, Bay x 3702. Brain Res 2000;858(1): 121-8.
  • Van Eldik LJ, Wainwright MS. The Janus face of glial derived S100B: beneficial and detrimental functions in the brain. Restor Neurol Neurosci 2003;21(3-4):97- 108.
  • Giussani DA, Thakor AS, Frulio R, Gazzolo D. Acute hypoxia increases S100beta protein in association with blood flow redistribution away from peripheral cir- culations in fetal sheep. Pediatr Res 2005;58(2):179- 84.
  • Oses JP, Leke R, Portela LV, et al. Biochemical brain markers and purinergic parameters in rat CSF after seizure induced by pentylenetetrazol. Brain Res Bull 2004; 64(2): 237-42.
  • Simonian NA, Coyle JT. Oxidative Stres in Neuro- degenerative Diseases. Ann Rev Pharmacol Toxicol 1996;36(1):83-106.
  • Michael T, Lin, M. Mitochondrial dysfunction and oxi- dative stress in neurodegenerative diseases. Nature 2006;443(3):787-95.
  • Li SW, Barger L, Liu RE, Mrak MST. S100b induction of the proinflammatory cytokine interleukin-6 in neu- rons. J Neurochem 2000;74(1):143-50.
  • Yuksel D, Yilmaz D, Uyar NY, Senbil N, Gurer Y, Anlar B. Tau proteins in the cerebrospinal fluid of patients with subacute sclerosing panencephalitis. Brain Dev 2010;32(3): 467-71.
  • Wiesmann M, Wandinger KP, Missler U, Eckhoff D, Rothermundt M, Arolt V, et al. Elevated plasma levels of S-100b protein in schizophrenic patients. Biol Psy- chiatry 1999;45:1508-11.
  • Chaves ML, Camozzato AL, Ferreira ED, et al. Se- rum levels of S100B and NSE proteins in Alzheimer’s disease patients. J Neuroinflammation 2010; 7(1):1-6.
  • Gazzolo D, Grutzfeld Dariusz, et al. Increased S100B in cerebrospinal fluid of infants with bacterial menin- gitis: Relationship to brain damage and routine cere- brospinal fluid findings. Clin Chem 2004;50(8):941-4.
There are 21 citations in total.

Details

Primary Language Turkish
Journal Section Research Article
Authors

İbrahim Hocanlı This is me

Mustafa Çalık This is me

Alpay Çakmak This is me

Hakim Çelik This is me

Addürrahim Koçyiğit This is me

Akın İşcan This is me

Publication Date September 1, 2012
Published in Issue Year 2012

Cite

APA Hocanlı, İ., Çalık, M., Çakmak, A., Çelik, H., et al. (2012). Subakut Sklerozan Panensefalit\’li çocuklarda serum S-100B düzeyleri. Journal of Clinical and Experimental Investigations, 3(3), 331-334. https://doi.org/10.5799/ahinjs.01.2012.03.0173
AMA Hocanlı İ, Çalık M, Çakmak A, Çelik H, Koçyiğit A, İşcan A. Subakut Sklerozan Panensefalit\’li çocuklarda serum S-100B düzeyleri. J Clin Exp Invest. September 2012;3(3):331-334. doi:10.5799/ahinjs.01.2012.03.0173
Chicago Hocanlı, İbrahim, Mustafa Çalık, Alpay Çakmak, Hakim Çelik, Addürrahim Koçyiğit, and Akın İşcan. “Subakut Sklerozan Panensefalit\’li çocuklarda Serum S-100B düzeyleri”. Journal of Clinical and Experimental Investigations 3, no. 3 (September 2012): 331-34. https://doi.org/10.5799/ahinjs.01.2012.03.0173.
EndNote Hocanlı İ, Çalık M, Çakmak A, Çelik H, Koçyiğit A, İşcan A (September 1, 2012) Subakut Sklerozan Panensefalit\’li çocuklarda serum S-100B düzeyleri. Journal of Clinical and Experimental Investigations 3 3 331–334.
IEEE İ. Hocanlı, M. Çalık, A. Çakmak, H. Çelik, A. Koçyiğit, and A. İşcan, “Subakut Sklerozan Panensefalit\’li çocuklarda serum S-100B düzeyleri”, J Clin Exp Invest, vol. 3, no. 3, pp. 331–334, 2012, doi: 10.5799/ahinjs.01.2012.03.0173.
ISNAD Hocanlı, İbrahim et al. “Subakut Sklerozan Panensefalit\’li çocuklarda Serum S-100B düzeyleri”. Journal of Clinical and Experimental Investigations 3/3 (September 2012), 331-334. https://doi.org/10.5799/ahinjs.01.2012.03.0173.
JAMA Hocanlı İ, Çalık M, Çakmak A, Çelik H, Koçyiğit A, İşcan A. Subakut Sklerozan Panensefalit\’li çocuklarda serum S-100B düzeyleri. J Clin Exp Invest. 2012;3:331–334.
MLA Hocanlı, İbrahim et al. “Subakut Sklerozan Panensefalit\’li çocuklarda Serum S-100B düzeyleri”. Journal of Clinical and Experimental Investigations, vol. 3, no. 3, 2012, pp. 331-4, doi:10.5799/ahinjs.01.2012.03.0173.
Vancouver Hocanlı İ, Çalık M, Çakmak A, Çelik H, Koçyiğit A, İşcan A. Subakut Sklerozan Panensefalit\’li çocuklarda serum S-100B düzeyleri. J Clin Exp Invest. 2012;3(3):331-4.